Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 May 2013
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Guidance on the use of electroconvulsive therapy (TA59)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 October 2009Published: 26 April 2003
Structural neuroimaging in first-episode psychosis (TA136)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2008
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Iclepertin for treating cognitive impairment associated with schizophrenia ID6483Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC